In 2023, the global biopharma CMO market size reached USD 17.41 billion, with projections to attain USD 39.31 billion by 2031, showcasing a dominant CAGR of 10.72%. Meanwhile, the global CDMO market size stands at USD 15.32 billion in 2024 and has a forecasted growth to USD 27.94 billion by 2029 at a CAGR of 12.78%.
While North America has traditionally dominated the CMO/CDMO market, the Asia Pacific region has emerged as the fastest-growing. Anticipated to experience a robust regional CAGR of 8.94% from 2024 to 2029, this growth is attributed to a rapidly expanding population driving demand for biolog-ics. Additional contributing factors include comparatively lower labour costs (as much as 30% lower in manufacturing alone), government policies and regulatory changes.
The 3rd Biologics Contract Manufacturing Asia 2024 is a premium event that focuses exclusively on Contract Manufacturing in Asia-Pacific. The conference addresses the growing market of contract manufacturing, the predicted trends in the market, challenges faced by CMOs/ CDMOs, as well as the solutions and opportunities moving forward. We bring the entire eco-system together — from experts in the biologics manufacturing space, to academia and regulatory — to foster partnerships, share insights and stay on the cutting edge of new developments.
